RT期刊文章SR电子T1的低频髓少突细胞糖蛋白抗体在日本Opticospinal多发性硬化症(P1.384)摩根富林明神经病学神经学乔FD Lippincott Williams &威尔金斯SP P1.384 VO 86是16补充A1 Sudarshini拉马纳坦A1 Shinya佐藤A1 Takuya松下A1 Katsuh首页isa正树A1良山崎裕A1罗素戴尔A1 Jun-ichi基拉A1 Fabienne Brilot年2016 UL //www.ez-admanager.com/content/86/16_Supplement/P1.384.abstract AB目的:鉴于选择性脊髓和视神经病理参与日本Opticospinal多发性硬化症患者(osm),和先前的调查结果反映,这些患者的比例水通道蛋白4 (AQP4)抗体,我们检查了一群AQP4 antibody-negative日本osm患者髓少突细胞糖蛋白抗体(MOG)。我们假设,一些患者osm MOG抗体阳性。背景:抗体MOG最近被确定在许多患者视neuromyelitis谱系障碍包括同步双边视神经炎(BON)或纵向广泛的横向脊髓炎(LETM)设计/方法:我们测试了五十日本患者的血清AQP4 antibody-negative osm以及四十的同龄日本控制是健康或其他神经系统疾病。MOG抗体检测使用流式细胞仪进行细胞实验与生活293年人类胚胎肾细胞人类MOG lentivirus-transduced表达完整的表面。结果:MOG抗体检测在2/50患者AQP4 antibody-negative日本osm和没有控制。MOG抗体阳性患者复发性单侧视神经炎,好,横向脊髓炎。第二个MOG抗体阳性患者出现复发性脊髓炎横,一集LETM。两个病人有一个有利的结果的视力和残疾的分数。值得注意的是,这两个MOG抗体阳性患者占4 1患者在这个osm组好,和唯一的病人与LETM osm组。结论:在看到女士在澳大利亚人口,MOG抗体在日本osm患者并不常见。 However, the clinical phenotype of BON or LETM may support MOG antibody testing in this group.Disclosure: Dr. Ramanathan has received personal compensation from NHMRC Australia and the Petre Foundation. Dr. Sato has nothing to disclose. Dr. Matsushita has received research support from Bayer Schering Pharma and Mitsubishi Tanabe Pharma. Dr. Masaki has nothing to disclose. Dr. Yamasaki has received research support from Bayer Schering Pharma, Biogen Idec, Novartis Pharma, and Mitsubish Tanabe Pharma. Dr. Dale has received research support from Star Scientific Foundation, Trish MS Research Foundation, MSRA, NHMRC Australia, and the Petre Foundation. Dr. Kira has received personal compensation for activities with Bayer Schering Pharma, Cosmic Corporation, and Biogen Idec Japan. Dr. Brilot-Turville has received research support from Star Scientic Foundation, Trish MS Research Foundation, MSRA, MS Angels Melbourne, NHMRC, and the Petre Foundation.Saturday, April 16 2016, 8:30 am-7:00 pm